Eurofins Scientific (ERF) Q2 2025 earnings summary

Executive summary

• Achieved record H1 2025 revenues of €3,612m, up 5.7% year-over-year, with organic growth of 3.9% and strong performance across most regions and end markets.

• Adjusted EBITDA rose 7.0% to €810m, with margin improving to 22.4%; net profit increased 12.3% to €247m and basic EPS grew 18.4% to €1.20.

• Completed 22 business combinations, including SYNLAB Spain, and expanded owned laboratory space by 30,000 m².

• Financial position strengthened by long-term refinancing of hybrid bonds and Schuldschein loans; leverage at 2.1x, within target range.

• Strategic focus on bolt-on acquisitions, digitalisation, and infrastructure expansion continues, with management confident in achieving 2027 targets.

Financial highlights

• Revenues reached €3,612m (+5.7% year-over-year); organic growth at 3.9% (2.9% excluding public working days adjustment).

• Adjusted EBITDA at €810m (+7.0%); adjusted EBITDA margin at 22.4% (+30bps year-over-year).

• Net profit €247m (+12.3%); basic EPS €1.20 (+18.4%).

• Free Cash Flow to the Firm before investment in owned sites was €354m (+3.8%); net working capital intensity improved to 5.5%.

• Net debt at €3,360m; leverage ratio 2.1x, within target range.

Outlook and guidance

• FY 2025 targets mid-single-digit organic growth and €250m in acquisition revenues consolidated at mid-year.

• Adjusted EBITDA margin expected to improve over FY 2024's 22.3%; FCFF before investment in owned sites to exceed €954m.

• FY 2027 objectives: 6.5% average organic growth, 24% adjusted EBITDA margin, and leverage trending to lower end of 1.5-2.5x range.

• Capital allocation prioritises high-growth start-ups, digitalisation, and proprietary IT; net operating capex expected at ~€400m p.a.

• Currency fluctuations, inflation, and M&A profitability may impact results.